STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.

ABSTRACT:

Purpose

Increased activity of STAT3 is associated with progression of head and neck squamous cell carcinoma (HNSCC). Upstream activators of STAT3, such as JAKs, represent potential targets for therapy of solid tumors, including HNSCC. In this study, we investigated the anticancer effects of ruxolitinib, a clinical JAK1/2 inhibitor, in HNSCC preclinical models, including patient-derived xenografts (PDX) from patients treated on a window-of-opportunity trial.

Experimental design

HNSCC cell lines were treated with ruxolitinib, and the impact on activated STAT3 levels, cell growth, and colony formation was assessed. PDXs were generated from patients with HNSCC who received a brief course of neoadjuvant ruxolitinib on a clinical trial. The impact of ruxolitinib on tumor growth an

SUBMITTER: Qureshy Z 

PROVIDER: S-EPMC10024606 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature